Latest news with #RSUs
Globe and Mail
11-07-2025
- Business
- Globe and Mail
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ('RSUs') representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics.
Globe and Mail
11-07-2025
- Business
- Globe and Mail
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July of an aggregate of 12,385 restricted stock units (RSUs) of the company's common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant date and vesting commencement date of July 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the stock option agreement or RSU agreement, as applicable, covering the grant, including requirements to remain continuously employed on each vesting date. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook.
Yahoo
11-07-2025
- Business
- Yahoo
FPX Nickel Announces Share-Based Compensation Grant
VANCOUVER, BC, July 11, 2025 /CNW/ - FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) ("FPX" or the "Company") announces that the board of directors of the Company has approved the grant of 5,305,000 stock options (the "Options") to directors, officers and employees of the Company pursuant to the Company's Share Compensation Plan. The Options have an exercise price of $0.30 per share, with a five-year term and are fully vested on the grant date, July 10, 2025. The Company also granted an aggregate 750,000 restricted share units (the "RSUs") to certain officers of the Company. The RSUs vest in three equal installments on the annual anniversaries of the grant date and each vested RSU will entitle the holder to receive one common share of the Company or the equivalent cash value upon settlement. About FPX Nickel Corp. FPX Nickel Corp. is focused on the exploration and development of the Decar Nickel District, located in central British Columbia, and other occurrences of the same unique style of naturally occurring nickel-iron alloy mineralization known as awaruite. For more information, please view the Company's website at or contact Martin Turenne, President and CEO, at (604) 681-8600 or ceo@ On behalf of FPX Nickel Corp. "Martin Turenne"Martin Turenne, President, CEO and Director Forward-Looking Statements Certain of the statements made and information contained herein is considered "forward-looking information" within the meaning of applicable Canadian securities laws. These statements address future events and conditions and so involve inherent risks and uncertainties, as disclosed in the Company's periodic filings with Canadian securities regulators. Actual results could differ from those currently projected. The Company does not assume the obligation to update any forward-looking statement. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. SOURCE FPX Nickel Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
11-07-2025
- Business
- Globe and Mail
FPX Nickel Announces Share-Based Compensation Grant
VANCOUVER, BC , July 11, 2025 /CNW/ - FPX Nickel Corp. (TSXV: FPX) (OTCQB: FPOCF) (" FPX" or the " Company") announces that the board of directors of the Company has approved the grant of 5,305,000 stock options (the " Options") to directors, officers and employees of the Company pursuant to the Company's Share Compensation Plan. The Options have an exercise price of $0.30 per share, with a five-year term and are fully vested on the grant date, July 10, 2025 . The Company also granted an aggregate 750,000 restricted share units (the " RSUs") to certain officers of the Company. The RSUs vest in three equal installments on the annual anniversaries of the grant date and each vested RSU will entitle the holder to receive one common share of the Company or the equivalent cash value upon settlement. About FPX Nickel Corp. FPX Nickel Corp. is focused on the exploration and development of the Decar Nickel District, located in central British Columbia , and other occurrences of the same unique style of naturally occurring nickel-iron alloy mineralization known as awaruite. For more information, please view the Company's website at or contact Martin Turenne , President and CEO, at (604) 681-8600 or ceo@ On behalf of FPX Nickel Corp. "Martin Turenne" Martin Turenne , President, CEO and Director Forward-Looking Statements Certain of the statements made and information contained herein is considered "forward-looking information" within the meaning of applicable Canadian securities laws. These statements address future events and conditions and so involve inherent risks and uncertainties, as disclosed in the Company's periodic filings with Canadian securities regulators. Actual results could differ from those currently projected. The Company does not assume the obligation to update any forward-looking statement. Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. SOURCE FPX Nickel Corp.
Yahoo
01-07-2025
- Business
- Yahoo
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of June 30, 2025. The stock option has an exercise price of $48.71 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. 'Quarterly Vesting Date' means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder. The foregoing equity awards were granted as inducements material to the employees entering into employment with Cidara, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Cidara, or following a bona fide period of non-employment, as an inducement material to such individual's entering into employment with Cidara, pursuant to Nasdaq Listing Rule 5635(c)(4). About Cidara Therapeutics Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of enrollment of its Phase 2b NAVIGATE trial in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit INVESTOR CONTACT: Brian Ritchie LifeSci Advisors (212) 915-2578 britchie@ MEDIA CONTACT: Michael Fitzhugh LifeSci Communications (628) 234-3889 mfitzhugh@
